Ensysce Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ensysce Biosciences, Inc. on April 3, 2026, covering events occurring on April 1, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "ENSC."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the resignation of Curtis Rosebraugh from the Board of Directors, effective April 1, 2026. Prior to his departure, Dr. Rosebraugh served as a member of the Nominating and Corporate Governance Committee.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items related to operations or finances. The document serves solely to disclose the director's resignation.
Key Facts for Investor Verification
- Dr. Curtis Rosebraugh resigned from the Board of Directors effective April 1, 2026.
- Dr. Rosebraugh was a member of the Nominating and Corporate Governance Committee.
- The resignation notice is attached as Exhibit 17 to this filing.
- The report was signed by Dr. Lynn Kirkpatrick, President and Chief Executive Officer.